Adherence to deferasirox in children and adolescents with sickle cell disease during 1-year of therapy

Ofelia A Alvarez, Hector Rodriguez-Cortes, Natasha Robinson, Noeline Lewis, Claudia Diaz Pow Sang, Gabriela Lopez-Mitnik, Carole Paley

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Background: Adherence to long-term treatment is challenging. Deferasirox (DFX) is a daily oral iron chelator approved in the United States for transfusional iron overload. PROCEDURES: Twenty-one subjects with sickle cell disease (mean age 13.8±4.2y) received DFX 20 to 30 mg/kg daily for 1-year while on chronic blood transfusions. Good adherence to DFX was defined as ≥80% intake of prescribed dose. Adherence was assessed by monthly pill counts and calendars, and questionnaires at 1, 3, 6, and 12 months follow-up. RESULTS: Fifteen of 21 subjects (71%) were adherent to DFX according to self-reports, with 83% of the patients being adherent at 1 month, 89% at 3 months, 65% at 6 months, and 78% at 12 months. We were only able to document continuous good adherence in 43% of patients by pill counts because of poor bottle return. The discrepancy between pill counts and self-reports may be related to over-reporting, with the real adherence being lower. Parental involvement with DFX administration (P=0.03) and age ≤16 years (P=0.0055) correlated with adherence. We could not detect a significant correlation between serum ferritin declines and adherence. Conclusion: Seventy-one percent of patients adhered to DFX according to questionnaire responses but only 43% did according to pill counts. Adherence was poorer in adolescents older than 16 years of age and in patients who had no parental supervision of medications.

Original languageEnglish
Pages (from-to)739-744
Number of pages6
JournalJournal of Pediatric Hematology/Oncology
Volume31
Issue number10
DOIs
StatePublished - Oct 1 2009

    Fingerprint

Keywords

  • Adherence
  • Children
  • Deferasirox
  • Sickle cell anemia
  • Sickle cell disease

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this